For state-by-state regulatory and compounding context relevant to research peptides, consult the Peptide Laws by State hub.
What Is Semaglutide?
Semaglutide (Ozempic for T2D, Wegovy for obesity) is a GLP-1 receptor agonist developed by Novo Nordisk that became one of the most commercially significant pharmaceuticals in history by 2024. Two amino acid substitutions and an attached C18 fatty acid chain via an aminobutyric acid linker enable albumin binding and extend its half-life to approximately 7 days, enabling once-weekly subcutaneous injection.
Quick Reference
Member reference tables summarize the compound's research parameters.
At 2.4mg weekly (Wegovy dose), semaglutide produces mean weight loss of 15–17% of body weight over 68 weeks in the STEP trials. This is achieved through GLP-1R activation in the hypothalamic arcuate nucleus (reducing hunger), slowed gastric emptying (extending satiety), and direct effects on food reward circuitry in the brainstem.
Cardiovascular Outcomes and Emerging Research
The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4mg in overweight or obese adults without diabetes — the first demonstration of cardiovascular benefit from a weight-loss drug in a non-diabetic population. Semaglutide is also being investigated for Alzheimer's disease (GLP-1R is expressed on neurons), alcohol and substance use disorder, MASH/NASH, chronic kidney disease, and sleep apnea.
Research Indications
Weight Loss
Supported Research
FDA-Approved Weight Management
Approved as Wegovy for chronic weight management with average 15-20% body weight reduction
Sustained Appetite Control
Reduces hunger and increases satiety through central GLP-1 receptor activation
Long-Term Weight Maintenance
Clinical trials show sustained weight loss over 2+ years with continued treatment
Diabetes
Supported Research
Comprehensive Glucose Control
FDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% and low hypoglycemia risk
Cardiovascular Benefits
Proven reduction in major cardiovascular events in high-risk diabetes patients
Flexible Treatment Options
Available as weekly injection (Ozempic), daily oral tablet for diabetes (Rybelsus), or daily oral tablet for weight management (oral Wegovy)
Metabolic
Preliminary Data
Metabolic Health Improvement
Addresses multiple metabolic parameters including weight, glucose, blood pressure, and lipids
Anti-Inflammatory Effects
Reduces systemic inflammation markers beyond weight loss effects
Liver Health Benefits
Emerging evidence for improvements in non-alcoholic fatty liver disease
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The listed research text specifies confirming the pen is labeled Ozempic (diabetes) or Wegovy (weight loss) from a licensed pharmacy. Legitimate pens are not available as loose vials — vial format indicates compounded or counterfeit product.
Verified Marker
Clear, Colorless to Slightly Yellow
Solution in the prefilled pen should be clear and colorless to slightly yellow. The product must not be used if it is cloudy or discolored, or if visible particles are present.
Verified Marker
Proper Cold Chain Maintained
The listed research text specifies confirming medication was refrigerated at 2–8°C during shipping and storage. An in-use pen may be kept at room temperature (≤30°C) for up to 56 days — discard if previously frozen.
Quality Concern
Compounded Injectable Semaglutide
FDA has specifically warned against unlicensed compounded semaglutide. If using a compounded formulation, verify the 503B outsourcing facility has current FDA registration and the product has been independently tested.
Verified Marker
FDA-Approved Rybelsus or Oral Wegovy
Only branded Rybelsus (3/7/14 mg for T2D) and Oral Wegovy (3→6→12→25 mg for obesity) are FDA-approved oral semaglutide products. No other oral GLP-1 products are approved.
Verified Marker
Intact Tablets in Blister Pack
Tablets should be whole and undamaged in original sealed blister packaging. Loose tablets or broken seals indicate improper handling or counterfeit product.
Verified Marker
Proper SNAC Formulation
Only Rybelsus and Oral Wegovy use SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption technology. Without SNAC, oral semaglutide is not absorbed — no other oral product has this.
Acceptable Range
No Approved Generic Available
No FDA-approved generic oral semaglutide exists. Any product marketed as a generic oral semaglutide is not a legitimate pharmaceutical.
Quality Concern
Crushed or Split Tablets
Tablets must never be altered in any way. Crushing or splitting destroys the SNAC coating and eliminates absorption entirely.
Quality Concern
Compounded Oral Semaglutide
Compounded oral semaglutide lacks SNAC technology and is not bioequivalent to Rybelsus or Oral Wegovy. FDA has specifically warned against these products.